@ethanjweiss There is no other industries that I can think of where the value to the organization paying for a product (insurance) is as removed from the value of the user (clinician).
Portugal is the country with the highest fully vaccinated population in the world (86%) and 98% age 12+. No Covid restrictions. All Delta.
Look what happens vs US with 30 per cent points lower fully vaccinated (56%)
https://t.co/5iL4cH2wbA @MarcSantoraNYT@RaphaelMinder
Welcome July! New month = new supplies.
Vanessa shared this great picture of her recent delivery… one month of NxStage HHD supplies. She will get these tucked away in the closet along with her other ancillary supplies and be on her way!
Being able to train in as few as 10 days* is a testament to NxStage systems being designed for simplicity & ease of use by patients at home. Healthcare training teams will always ensure that patients can safely perform their treatments before going home. Training times may vary.
The STEMI DTU randomized controlled trial will study unloading with the #Impella heart pump as a therapy to reduce heart failure risk. https://t.co/pksl5N5VWn
Case today illustrates the value of MCS in preserved EF. 18 yo SVG to LAD also supplying collaterals to the RCA which was CTO. High grade LM to Lcx. During 🎈inflation of SVG loss of pulse pressure. IVUS guided SVG and LM LCX successfully treated. Preserved native LAD option
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration pre-market approval for safety and efficacy in the therapy of cardiogenic shock for up to 14 days. https://t.co/G0pq8z6I3P
Great job. Shows that shock patients benefit from PAC (swans). The escape trial was not shock patients. This fits nicely with our hemodynamic criteria “mandate” in the new shock definition. @SCAI@HFSA@davebaran@HenrytTimothy@DrCindyGrines